Prostate cancer can be difficult to diagnose without an invasive procedure, such as a tissue biopsy, to confirm the presence of cancerous cells. City of Hope researchers validated that a nanodevice they developed could distinguish between prostate cancer and benign prostatic hyperplasia.

A study by City of Hope researchers reveals that many patients classified by National Comprehensive Cancer Network (NCCN) guidelines as “very low risk” did have higher risk prostate cancer after a complete pathological examination was performed.

Almost 60 percent of American cancer patients are over 65 years old, but this age group only represents 33 percent of the clinical trial population. Furthermore, many studies did not report any participants above the age of 75 — although this group makes up approximately 30 percent of patients with cancer.

City of Hope researchers developed a combination therapy to treat late-stage type 1 diabetes that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study is published in the May 9 edition of Science Translational Medicine.

City of Hope researchers have shown how leukemia stem cells hijack the bone marrow where they live, helping them to proliferate, potentially outlast powerful therapy and return to cause cancer.